CADM2: Protein Involved in Cell-cell Adhesion and Cancer Progression

Target Name: CADM2

NCBI ID: G253559

CADM2: Protein Involved in Cell-cell Adhesion and Cancer Progression

CADM2 (Cadherin-associated protein 2) is a protein that is expressed in various tissues throughout the body, including epithelial, endothelial, and mesenchymal cells. It is a member of the cadherin family of transmembrane proteins, which are involved in cell-cell adhesion and tissue organization.

One of the key functions of CADM2 is its role in cell-cell adhesion. CADM2 is a critical protein for the development and maintenance of tight junctions, which are specialized junctions that allow cells to exchange nutrients, waste products, and other substances while keeping their cell contents isolated from the surrounding environment. cadm2 is involved in the formation of these specialized junctions by interacting with a variety of other proteins, including E-cadherin and N-cadherin.

Another important function of CADM2 is its role in cancer progression. cadm2 has been shown to be involved in the development and progression of various types of cancer, including breast, ovarian, and prostate cancer. It has been shown to promote the growth and survival of cancer cells, and to play a role in the development of resistance to chemotherapy.

CADM2 is also a potential drug target. Researchers have identified several potential drug candidates that target CADM2, and are in the process of testing them in clinical trials. These drugs are designed to inhibit the activity of CADM2, either by blocking its interaction with other proteins , or by inhibiting its own activity.

One of the most promising drug candidates for CADM2 is a small molecule called NECL-3. NECL-3 is a inhibitor of CADM2 that is currently being tested in clinical trials for the treatment of various types of cancer. Studies have shown that NECL-3 is able to inhibit the activity of CADM2, and to lead to the regression of cancer cells that have been established in cell culture.

Another potential drug candidate for CADM2 is a monoclonal antibody called AMG 3016. This antibody is designed to target CADM2, and is being tested in clinical trials for the treatment of various types of cancer.

In conclusion, CADM2 is a protein that is involved in a variety of important functions in the body, including cell-cell adhesion and cancer progression. It is also a potential drug target, and several promising drug candidates are currently being tested in clinical trials to inhibit its activity. Further research is needed to fully understand the role of CADM2 in these processes, and to develop safe and effective treatments for the various types of cancer that are caused by its overexpression.

Protein Name: Cell Adhesion Molecule 2

Functions: Adhesion molecule that engages in homo- and heterophilic interactions with the other nectin-like family members, leading to cell aggregation. Important for synapse organization, providing regulated trans-synaptic adhesion. Preferentially binds to oligodendrocytes

More Common Targets